Literature DB >> 22151568

Methadone in the intrathecal treatment of chronic nonmalignant pain resistant to other neuroaxial agents: the first experience.

Y Eugene Mironer1, C David Tollison1.   

Abstract

Intrathecal drug delivery is a widely used and effective method of treatment for chronic intractable pain. Unfortunately all currently used agents can not provide adequate pain relief in all patients. A prospective study of neuroaxial methadone was performed in 24 patients, all of whom had failed treatment with multiple previous intrathecal drugs. Thirteen patients experienced improvement of their pain control with methadone, nine continued to receive this agent for 6 months with good pain relief, improved quality of life and no side effects. The final rates of methadone infusion were 2.2 times higher than preceding morphine rates. The only observed possible side effect of methadone was transient blurred vision in one patient. Methadone is a promising alternative neuroaxial agent in the treatment of chronic pain.

Entities:  

Year:  2001        PMID: 22151568     DOI: 10.1046/j.1525-1403.2001.00025.x

Source DB:  PubMed          Journal:  Neuromodulation        ISSN: 1094-7159


  22 in total

1.  Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists.

Authors:  Per Sjøgren; Niels-Henrik Jensen; Troels Staehelin Jensen
Journal:  Pain       Date:  1994-11       Impact factor: 6.961

2.  Intraspinal morphine for chronic pain: a retrospective, multicenter study.

Authors:  J A Paice; R D Penn; S Shott
Journal:  J Pain Symptom Manage       Date:  1996-02       Impact factor: 3.612

Review 3.  Clinical realities and economic considerations: efficacy of intrathecal pain therapy.

Authors:  J A Paice; W Winkelmüller; K Burchiel; G B Racz; J P Prager
Journal:  J Pain Symptom Manage       Date:  1997-09       Impact factor: 3.612

Review 4.  Clinical realities and economic considerations: special therapeutic issues in intrathecal therapy--tolerance and addiction.

Authors:  R K Portenoy; S R Savage
Journal:  J Pain Symptom Manage       Date:  1997-09       Impact factor: 3.612

5.  Morphine-3-glucuronide--a potent antagonist of morphine analgesia.

Authors:  M T Smith; J A Watt; T Cramond
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

6.  Methadone in pain uncontrolled by morphine.

Authors:  J S Morley; J W Watt; J C Wells; J B Miles; M J Finnegan; G Leng
Journal:  Lancet       Date:  1993-11-13       Impact factor: 79.321

7.  Intrathecal infusional therapies for intractable pain: patient management guidelines.

Authors:  E S Krames
Journal:  J Pain Symptom Manage       Date:  1993-01       Impact factor: 3.612

8.  Long-term intraspinal infusions of opioids in the treatment of neuropathic pain.

Authors:  S J Hassenbusch; M Stanton-Hicks; E C Covington; J G Walsh; D S Guthrey
Journal:  J Pain Symptom Manage       Date:  1995-10       Impact factor: 3.612

9.  Intrathecal infusional analgesia for nonmalignant pain: analgesic efficacy of intrathecal opioid with or without bupivacaine.

Authors:  E S Krames; R M Lanning
Journal:  J Pain Symptom Manage       Date:  1993-11       Impact factor: 3.612

View more
  4 in total

Review 1.  Implantable intrathecal pumps for chronic pain: highlights and updates.

Authors:  Karen H Knight; Frances M Brand; Ali S Mchaourab; Giorgio Veneziano
Journal:  Croat Med J       Date:  2007-02       Impact factor: 1.351

Review 2.  Spinal drug delivery.

Authors:  T S Grabow; D Derdzinski; P S Staats
Journal:  Curr Pain Headache Rep       Date:  2001-12

Review 3.  Long-term opioid management for chronic noncancer pain.

Authors:  Meredith Noble; Jonathan R Treadwell; Stephen J Tregear; Vivian H Coates; Philip J Wiffen; Clarisse Akafomo; Karen M Schoelles
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

4.  Long-term opioid treatment of chronic nonmalignant pain: unproven efficacy and neglected safety?

Authors:  Igor Kissin
Journal:  J Pain Res       Date:  2013-07-04       Impact factor: 3.133

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.